Cargando…

The power of modelling pulsatile profiles

The quantitative description of individual observations in non-linear mixed effects models over time is complicated when the studied biomarker has a pulsatile release (e.g. insulin, growth hormone, luteinizing hormone). Unfortunately, standard non-linear mixed effects population pharmacodynamic mode...

Descripción completa

Detalles Bibliográficos
Autores principales: van Esdonk, Michiel J., Stevens, Jasper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144129/
https://www.ncbi.nlm.nih.gov/pubmed/33660229
http://dx.doi.org/10.1007/s10928-021-09743-2
_version_ 1783696896408158208
author van Esdonk, Michiel J.
Stevens, Jasper
author_facet van Esdonk, Michiel J.
Stevens, Jasper
author_sort van Esdonk, Michiel J.
collection PubMed
description The quantitative description of individual observations in non-linear mixed effects models over time is complicated when the studied biomarker has a pulsatile release (e.g. insulin, growth hormone, luteinizing hormone). Unfortunately, standard non-linear mixed effects population pharmacodynamic models such as turnover and precursor response models (with or without a cosinor component) are unable to quantify these complex secretion profiles over time. In this study, the statistical power of standard statistical methodology such as 6 post-dose measurements or the area under the curve from 0 to 12 h post-dose on simulated dense concentration–time profiles of growth hormone was compared to a deconvolution-analysis-informed modelling approach in different simulated scenarios. The statistical power of the deconvolution-analysis-informed approach was determined with a Monte-Carlo Mapped Power analysis. Due to the high level of intra- and inter-individual variability in growth hormone concentrations over time, regardless of the simulated effect size, only the deconvolution-analysis informed approach reached a statistical power of more than 80% with a sample size of less than 200 subjects per cohort. Furthermore, the use of this deconvolution-analysis-informed modelling approach improved the description of the observations on an individual level and enabled the quantification of a drug effect to be used for subsequent clinical trial simulations.
format Online
Article
Text
id pubmed-8144129
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-81441292021-06-01 The power of modelling pulsatile profiles van Esdonk, Michiel J. Stevens, Jasper J Pharmacokinet Pharmacodyn Original Paper The quantitative description of individual observations in non-linear mixed effects models over time is complicated when the studied biomarker has a pulsatile release (e.g. insulin, growth hormone, luteinizing hormone). Unfortunately, standard non-linear mixed effects population pharmacodynamic models such as turnover and precursor response models (with or without a cosinor component) are unable to quantify these complex secretion profiles over time. In this study, the statistical power of standard statistical methodology such as 6 post-dose measurements or the area under the curve from 0 to 12 h post-dose on simulated dense concentration–time profiles of growth hormone was compared to a deconvolution-analysis-informed modelling approach in different simulated scenarios. The statistical power of the deconvolution-analysis-informed approach was determined with a Monte-Carlo Mapped Power analysis. Due to the high level of intra- and inter-individual variability in growth hormone concentrations over time, regardless of the simulated effect size, only the deconvolution-analysis informed approach reached a statistical power of more than 80% with a sample size of less than 200 subjects per cohort. Furthermore, the use of this deconvolution-analysis-informed modelling approach improved the description of the observations on an individual level and enabled the quantification of a drug effect to be used for subsequent clinical trial simulations. Springer US 2021-03-03 2021 /pmc/articles/PMC8144129/ /pubmed/33660229 http://dx.doi.org/10.1007/s10928-021-09743-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
van Esdonk, Michiel J.
Stevens, Jasper
The power of modelling pulsatile profiles
title The power of modelling pulsatile profiles
title_full The power of modelling pulsatile profiles
title_fullStr The power of modelling pulsatile profiles
title_full_unstemmed The power of modelling pulsatile profiles
title_short The power of modelling pulsatile profiles
title_sort power of modelling pulsatile profiles
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144129/
https://www.ncbi.nlm.nih.gov/pubmed/33660229
http://dx.doi.org/10.1007/s10928-021-09743-2
work_keys_str_mv AT vanesdonkmichielj thepowerofmodellingpulsatileprofiles
AT stevensjasper thepowerofmodellingpulsatileprofiles
AT vanesdonkmichielj powerofmodellingpulsatileprofiles
AT stevensjasper powerofmodellingpulsatileprofiles